Patients with stage IV ovarian cancer can derive long-term benefits from neoadjuvant pembrolizumab and chemotherapy if they achieve a major pathologic response, according to research published in ...

Clinical findings show association between nadunolimab and lower incidence and later onset of CIPNPreclinical data show prevention of ...

Clinical findings show association between nadunolimab and lower incidence and later onset of CIPN Preclinical data show ...

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of ...

Recent investigation focuses on the effects of BRCA1 and BRCA2 tumor pathogenic variants (tPVs) within the parameters of two ...

Enfortumab vedotin is now available for patients who received prior platinum-containing chemotherapy and a PD-1/L1 inhibitor ...

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic ...

All cases were confirmed as malignant tumors by histopathology or cytology. 2. Patients underwent chemotherapy with platinum-based or taxane agents and subsequently developed sensor neuropathy ...

State Key Laboratory of Southwestern Chinese Medicine Resources, School of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, China ...

In ovarian cancer, evidence-based medicine usually favors taxol plus carboplatin as induction ... Increasing evidence suggests that chemotherapy in hormone-refractory prostate cancer improves ...

This single-arm, phase II trial (NCT04475016) evaluated a neoadjuvant regimen of four cycles of toripalimab (anti-PD-1 antibody), nimotuzumab (anti-EGFR antibody), and taxol-based chemotherapy (TNT), ...

Brooke Green, their Democratic colleague going through cancer, by shaving their heads in solidarity of her starting chemo.